Literature DB >> 17898347

Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia.

Ganesan Venkatasubramanian1, Seetharamaiah Chittiprol, Narendran Neelakantachar, Magadi N Naveen, Jagadisha Thirthall, Bangalore N Gangadhar, K Taranath Shetty.   

Abstract

OBJECTIVE: The purpose of this study was to examine the evidence for the insulin-like growth factor-1 (IGF-1) deficiency hypothesis in the pathogenesis of schizophrenia.
METHOD: The authors examined the fasting plasma levels of glucose, insulin, IGF-1, and cortisol in antipsychotic-naive schizophrenia patients (N=44) relative to age- and sex-matched healthy comparison subjects (N=44). Patients and comparison subjects were also matched for anthropometric measures and physical activity.
RESULTS: Schizophrenia patients had a significantly higher mean plasma insulin level as well as a significantly higher mean insulin resistance score relative to healthy comparison subjects. The mean plasma IGF-1 level was significantly lower in patients. IGF-1 levels had a significant negative correlation with plasma insulin levels. The total positive symptoms score as well as the hallucinations subscore had a significant inverse relationship with IGF-1 levels.
CONCLUSIONS: Deficient IGF-1 might underlie insulin resistance in schizophrenia. The IGF-1 deficit in antipsychotic-naive schizophrenia patients and its significant correlation with psychopathology scores suggest that IGF-1 might be potentially involved in the pathogenesis of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17898347     DOI: 10.1176/appi.ajp.2007.07020233

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  62 in total

Review 1.  Neurodevelopmental effects of insulin-like growth factor signaling.

Authors:  John O'Kusky; Ping Ye
Journal:  Front Neuroendocrinol       Date:  2012-06-16       Impact factor: 8.606

2.  Antipsychotic drugs activate the C. elegans akt pathway via the DAF-2 insulin/IGF-1 receptor.

Authors:  Kathrine R Weeks; Donard S Dwyer; Eric J Aamodt
Journal:  ACS Chem Neurosci       Date:  2010-03-25       Impact factor: 4.418

3.  Adjuvant metformin worsens psychosis in schizophrenia: a case report.

Authors:  Ganesan Venkatasubramanian; Rashmi Arasappa; Naren P Rao; Rishikesh V Behere; Bangalore N Gangadhar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

4.  Glucose abnormalities in the siblings of people with schizophrenia.

Authors:  Emilio Fernandez-Egea; Miguel Bernardo; Eduard Parellada; Azucena Justicia; Clemente Garcia-Rizo; Enric Esmatjes; Ignacio Conget; Brian Kirkpatrick
Journal:  Schizophr Res       Date:  2008-06-02       Impact factor: 4.939

Review 5.  Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria.

Authors:  Robin Murray; Christoph U Correll; Gavin P Reynolds; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2017-03-01

6.  Glucose metabolism dysregulation at the onset of mental illness is not limited to first episode psychosis: A systematic review and meta-analysis.

Authors:  Suat Kucukgoncu; Urska Kosir; Elton Zhou; Erin Sullivan; Vinod H Srihari; Cenk Tek
Journal:  Early Interv Psychiatry       Date:  2018-10-02       Impact factor: 2.732

7.  Sex difference in the association of body mass index and BDNF levels in Chinese patients with chronic schizophrenia.

Authors:  Fang Yang; Keming Wang; Xiangdong Du; Huiqiong Deng; Hanjing Emily Wu; Guangzhong Yin; Yuping Ning; Xingbing Huang; Antonio L Teixeira; João de Quevedo; Jair C Soares; Xiaosi Li; XiaoE Lang; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2018-11-19       Impact factor: 4.530

Review 8.  Is schizophrenia a syndrome of accelerated aging?

Authors:  Brian Kirkpatrick; Erick Messias; Philip D Harvey; Emilio Fernandez-Egea; Christopher R Bowie
Journal:  Schizophr Bull       Date:  2007-12-21       Impact factor: 9.306

9.  S100B Serum Levels in Schizophrenia Are Presumably Related to Visceral Obesity and Insulin Resistance.

Authors:  Johann Steiner; Aye Mu Myint; Kolja Schiltz; Sabine Westphal; Hans-Gert Bernstein; Martin Walter; Matthias L Schroeter; Markus J Schwarz; Bernhard Bogerts
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-06-10

10.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.